Literature DB >> 6704458

Dexamethasone in electroconvulsive therapy: efficacy for depression and post-ECT amnesia.

R L Horne, H M Pettinati, M Menken, A A Sugerman, E Varga, G F Wilson.   

Abstract

Dexamethasone, compared to placebo in a double-blind study, failed to prevent the memory deficiency that typically accompanies electroconvulsive therapy (ECT) (n = 48 patients treated for DSM-III diagnosed major depressive disorder). Rather, the administration of the drug was associated with attention (p less than 0.02) and short-term memory (p less than 0.0003) difficulties in both bilateral and unilateral ECT patients. Bilateral ECT plus dexamethasone patients had significantly less improvement (p less than 0.05) in their depression (measured by the Hamilton Depression Scale) compared to bilateral ECT plus placebo patients. These depression differences were not seen among unilateral ECT patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704458

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

1.  Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia.

Authors:  Chittaranjan Andrade; Shahid Ahmad Shaikh; Lakshmy Narayan; Christine Blasey; Joseph Belanoff
Journal:  J Neural Transm (Vienna)       Date:  2011-09-16       Impact factor: 3.575

2.  Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial.

Authors:  Arash Mohagheghi; Asghar Arfaie; Shahrokh Amiri; Masoud Nouri; Salman Abdi; Salman Safikhanlou
Journal:  Biomed Res Int       Date:  2015-04-06       Impact factor: 3.411

3.  Comparison between the effect of liothyronine and piracetam on personal information, orientation and mental control in patients under treatment with ECT.

Authors:  Mousavi Seyed Ghafur; Mohammad Saadat; Mohamad Reza Maraci; Reza S Bagherian; Mina Mazaheri
Journal:  Indian J Psychiatry       Date:  2012-04       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.